U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761136
Company: CELGENE CORP
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
REBLOZYL LUSPATERCEPT-AAMT 25MG/VIAL POWDER;SUBCUTANEOUS Prescription None No No
REBLOZYL LUSPATERCEPT-AAMT 75MG/VIAL POWDER;SUBCUTANEOUS Prescription None No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/03/2020 ORIG-2 Approval N/A; Orphan Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761136Orig2s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761136Orig2s000TOC.cfm
11/08/2019 ORIG-1 Approval N/A; Orphan Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761136Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761136Orig1s000TOC.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
05/16/2024 SUPPL-10 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761136s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761136Orig1s010ltr.pdf
08/28/2023 SUPPL-9 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761136s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761136Orig1s009ltr.pdf
07/08/2022 SUPPL-6 Supplement Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761136s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761136Orig1s006ltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
05/16/2024 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761136s010lbl.pdf
08/28/2023 SUPPL-9 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761136s009lbl.pdf
07/08/2022 SUPPL-6 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761136s006lbl.pdf
07/08/2022 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761136s006lbl.pdf
04/03/2020 ORIG-2 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf
11/08/2019 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf
Back to Top